NEW YORK (
CHANGE IN RATINGS
upgraded at Wells to Outperform, Wells Fargo said. Company has good earnings visibility and momentum.
rated new Neutral at Credit Suisse. $21 price target. Company will likely need to find more acquisitions to continue growing.
downgraded at DA Davidson from Buy to Neutral, DA Davidson said. Valuation call, based on a $3 price target.
rated new Buy at Sterne Agee. $53 price target. Slowdown in the Asia/US trade may be turning.
upgraded at Citigroup to Buy from Neutral, Citigroup said. $100 price target. Watch performance readthroughs strong.
rated new Equal-weight at Morgan Stanley. Company will likely grow slower than its peers over the next several quarters.
rated new Outperform at Credit Suisse. $44 price target. Company is leveraged to higher industry activity and pricing.
upgraded at Jefferies to Buy from Hold, Jefferies said. $30 price target. Focused on improving ROIC. Buy rating.
downgraded to sell at TheStreet Ratings.
downgraded to hold at TheStreet Ratings.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Stock is attractive, following the recent pullback. Menthol market is likely not as bad as feared.
The Medicines Company
upgraded at Jefferies to Buy from Hold, Jefferies said. $34 price target. Attractive risk reward.
Marsh & McLennan
rated new Neutral at MKM.Valuation call, based on a $34 price target.
downgraded at Citigroup to Neutral from Buy, Citigroup said. $23 price target. Valuation call.
upgraded at Bernstein to Market Perform from Underperform, Bernstein said. $6 price target. Softbank investment improves the company's finances.
Sprint Nextel downgraded at Hudson Square to Hold from Buy, Hudson Square said. Valuation call, as the Softbank deal dilutes future earnings.
Sprint Nextel upgraded at Baird to Neutral from Underperform, Robert Baird said. $6 price target. Despite Softbank investment, the company still faces competitive and structural challenges.
rated new Neutral at Credit Suisse. Valuation call, based on a $66 price target.
downgraded at Baird from Outperform to Neutral, Robert Baird said. $80 price target. International airfreight trends are tracking lower.
STOCK COMMENTS / EPS CHANGES
target raised at Jefferies t o $198, Jefferies said. ETF fee cuts less than feared. Hold rating.
estimates, target boosted at JMP. Shares of C now seen reaching $26, according to JMP Securities. Estimates also upped, given higher expected mortgage production. Underperform rating.
estimates, target cut at JP Morgan. CLH estimates were reduced through 2013, JP Morgan said. Company is leveraged to bad weather and lower rental equipment usage. Overweight rating and new $65 price target.
estimates, target raised at Guggenheim.Shares of COST now seen reaching $98, according to Guggenheim. Estimates also increased, as the company is cutting costs and seeing higher membership income.
estimates, target increased at Lazard.DISCA estimates were raised through 2013, Lazard said. Company can continue to deliver above-average audience growth. Buy rating and new $77 price target.
numbers raised at UBS. Shares of GCI now seen reaching $19, UBS said. Estimates also raised on strong publishing / broadcast. Neutral rating.
numbers lowered at Jefferies. Shares of MCHP now seen reaching $38, Jefferies said. Estimates also lowered on negative pre-announcement. Buy rating.
Microchip estimates, target cut at Credit Suisse. Shares of MCHP now seen reaching $38, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Outperform rating.
estimates, target cut at MKM. Shares of MSFT now seen reaching $32, according to MKM Partners. Estimates also reduced, Company is seeing slower Windows growth. Neutral rating.
target cut at UBS to $40.50, UBS said. Inexpensive, but faces long term challenges. Buy rating.
added to US 1 List at BofA/Merrill. Company can deliver solid, visible and predictable operating growth.
numbers lowered at Jefferies. TShares of TEN now seen reaching $34, Jefferies said. Estimates also lowered on weakness in Global CV and Europe. Buy rating.
estimates, target reduced at Canaccord. TEVA estimates were cut through 2013, Canaccord Genuity said. Company is facing a lower US generic outlook. Buy rating and new $50 price target.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.